3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Plasma cell
1
Classical hematology
1
Conditions
Venous Thromboembolism
10
Pulmonary Embolism
4
Venous Thrombosis
3
Neoplasms
3
Thrombosis
2
Multiple Myeloma
2
Urinary Bladder Neoplasms
1
Thromboprophylaxis
1
Thromboembolism
1
Thrombocytopenia
1
Neoplasms, Plasma Cell
1
Lymphoma
1
Leukemia
1
Hematologic Neoplasms
1
Head and Neck Neoplasms
1
Glioma
1
Glioblastoma
1
Fibrosis
1
Embolism
1
Carcinoma, Hepatocellular
1
Astrocytoma
1
Interventions
Dexamethasone
17
Lenalidomide
15
Bortezomib
12
Cyclophosphamide
7
fludarabine
6
carfilzomib
6
Melphalan
6
daratumumab
5
Calcium Dobesilate
5
pomalidomide
3
gamma-Globulins
3
fludarabine phosphate
3
belantamab mafodotin
3
Whole-Body Irradiation
3
Trimethoprim, Sulfamethoxazole Drug Combination
3
Tacrolimus
3
Mycophenolic Acid
3
isatuximab
2
elotuzumab
2
Sirolimus
2
Prednisone
2
Immunoglobulins, Intravenous
2
Granulocyte Colony-Stimulating Factor
2
Etoposide
2
Ciprofloxacin
2
Amoxicillin-Potassium Clavulanate Combination
2
venetoclax
1
thymoglobulin
1
siltuximab
1
poly ICLC
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Neoplasms, Plasma Cell
×
apixaban
×
1 year
×
Clear all
NCT02066454
2025-08-13
MYELAXAT
University Hospital, Grenoble
Phase 3
Completed
108 enrolled